| Autor: |
Robin Maximilian Awad, Fien Meeus, Hannelore Ceuppens, Thomas Ertveldt, Heleen Hanssens, Quentin Lecocq, Lukasz Mateusiak, Katty Zeven, Hana Valenta, Timo W.M. De Groof, Yannick De Vlaeminck, Ahmet Krasniqi, Kim De Veirman, Cleo Goyvaerts, Matthias D’Huyvetter, Sophie Hernot, Nick Devoogdt, Karine Breckpot |
| Přispěvatelé: |
Laboratory of Molecullar and Cellular Therapy, Basic (bio-) Medical Sciences, Faculty of Medicine and Pharmacy, Supporting clinical sciences, Clinical sciences, Medical Imaging, Hematology |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
International Review of Cell and Molecular Biology ISBN: 9780323994026 |
| Popis: |
Cancer is a heterogeneous disease, requiring treatment tailored to the unique phenotype of the patient's tumor. Monoclonal antibodies (mAbs) and variants thereof have enabled targeted therapies to selectively target cancer cells. Cancer cell-specific mAbs have been used for image-guided surgery and targeted delivery of radionuclides or toxic agents, improving classical treatment strategies. Cancer cell-specific mAbs can further inhibit tumor cell growth or can stimulate immune-mediated destruction of cancer cells, a feature that has also been achieved through mAb-mediated manipulation of immune cells and pathways. Drawbacks of mAbs and their variants, together with the discovery of camelid heavy chain-only antibodies and the many advantageous features of their variable domains, referred to as VHHs, single domain antibodies or nanobodies (Nbs), resulted in the exploration of Nbs as an alternative targeting moiety. We therefore review the state-of-the-art as well as novel exploitation strategies of Nbs for targeted cancer therapy. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
